Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐IFNα‐2a as Treatment for Chronic Hepatitis Delta
Open Access
- 24 January 2025
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 45 (2) , e70008
Abstract
Background and Aim: Bulevirtide (BLV) leads to beneficial virologic and biochemical responses when given alone to treat hepatitis delta virus (HDV) infection, which causes the most severe form of chronic viral hepatitis. We evaluated 48 weeks of BLV monotherapy, BLV + tenofovir disoproxil fumarate (TDF) and BLV + pegylated interferon alfa‐2a (Peg‐IFNα‐2a), with 24‐week follow‐up.Methods: Ninety patients were enrolled into six arms of 15 each (A–F); 60 patients were included in the main randomisation (arms A–D), and 30 patients (arms E–F) were randomised to the extension phase: (A) Peg‐IFNα‐2a 180 μg once weekly (QW); (B) BLV 2 mg once daily (QD) + Peg‐IFNα‐2a 180 μg QW; (C) BLV 5 mg QD + Peg‐IFNα‐2a 180 μg QW; (D) BLV 2 mg QD; (E) BLV 10 mg QD + Peg‐IFNα‐2a 180 μg QW and (F) BLV 10 mg (5 mg twice daily) + TDF QD. The primary endpoint was undetectable HDV RNA at week (W)72.Results: At W72, 53%, 27%, 7%, 7% and 33% of patients achieved undetectable HDV RNA in arms B, C, D, E and F, respectively, versus 0% in arm A. More arm B versus A patients had a > 1 log10 IU/mL decline in or loss of hepatitis B surface antigen (HBsAg) at W72 (p = 0.017), including four patients with loss of HBsAg. Bile acid elevations were dose‐dependent and reversible following the completion of BLV treatment.Conclusions: BLV combined with Peg‐IFNα‐2a was well tolerated and resulted in high rates of HDV RNA undetectability off‐treatment.Trial Registration: NCT02888106Keywords
Funding Information
- Deutsches Zentrum für Infektionsforschung
This publication has 23 references indexed in Scilit:
- The global prevalence of hepatitis D virus infection: Systematic review and meta-analysisJournal of Hepatology, 2020
- Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis deltaJournal of Viral Hepatitis, 2020
- Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trialThe Lancet Infectious Diseases, 2019
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionJournal of Hepatology, 2017
- Hepatitis D Virus ReplicationCold Spring Harbor Perspectives in Medicine, 2015
- Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-Specific Entry into HepatocytesGastroenterology, 2014
- Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis DeltaHepatology, 2014
- Hepatitis delta virusThe Lancet, 2011
- Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis DeltaNew England Journal of Medicine, 2011